<DOC>
	<DOCNO>NCT01185340</DOCNO>
	<brief_summary>The primary objective study ass whether LY2216684 12 mg 18 mg flexible dose daily superior placebo Once Daily adjunctive treatment patient major depressive disorder ( MDD ) partial responder Selective Serotonin Reuptake Inhibitor Treatment ( SSRI ) .</brief_summary>
	<brief_title>A Study Patients With Major Depressive Disorder Who Are Partial Responders Selective Serotonin Reuptake Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Women childbearing potential may participate must test negative pregnancy time study entry ; women/men agree use reliable method birth control Are treat one follow SSRIs : escitalopram , citalopram , sertraline , fluoxetine , paroxetine , fluvoxamine ; least 6 week prior investigational product dispense least last 4 week stable , optimized dose Drug dosage within label guideline specific country Meet criterion MDD , define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text RevisionÂ® ( DSMIVTR ) criteria Meet criterion partial response , define investigator 's opinion patient experience minimal clinically meaningful improvement SSRI Have GRID 17Item Hamilton Depression Rating Scale ( GRIDHAMD17 ) total score great equal 16 screen Have le equal 75 % improvement current SSRI screening determine Massachusetts General Hospital Antidepressant Treatment Response Questionnaire ( MGHATRQ ) Have currently additional ongoing DSMIVTR Axis 1 condition major depression within 1 year screening Have anxiety disorder consider primary diagnosis within past year ( include panic disorder , obsessivecompulsive disorder [ OCD ] , posttraumatic stress disorder [ PTSD ] , generalize anxiety disorder [ GAD ] , social phobia , exclude specific phobia ) Have current previous diagnosis bipolar disorder , schizophrenia , psychotic disorder Have history substance abuse and/or dependence within past 1 year ( drug category define DSMIVTR ) , include caffeine nicotine Have Axis II disorder , judgment investigator , would interfere compliance protocol Unstable medical condition contraindicate use LY2216684 Have diagnose medical condition could exacerbate noradrenergic agent include unstable hypertension , unstable heart disease , tachycardia , tachyarrhythmia , narrowangled glaucoma , history urinary hesitancy retention Use exclude concomitant psychotropic medication SSRI Have initiate discontinue hormone therapy within previous 3 month prior enrollment History treatment resistant depression show lack response current depressive episode 2 adequate course antidepressant therapy clinically appropriate dose least 4 week , judgment investigator , patient treatmentresistant depression Have lifetime history vagal nerve stimulation ( VNS ) transcranial magnetic stimulation ( TMS ) , psychosurgery Have receive electroconvulsive therapy ( ECT ) past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>MDD</keyword>
</DOC>